CN112771073B - 胰高血糖素样肽2(glp-2)类似物的制剂 - Google Patents

胰高血糖素样肽2(glp-2)类似物的制剂 Download PDF

Info

Publication number
CN112771073B
CN112771073B CN201980063594.1A CN201980063594A CN112771073B CN 112771073 B CN112771073 B CN 112771073B CN 201980063594 A CN201980063594 A CN 201980063594A CN 112771073 B CN112771073 B CN 112771073B
Authority
CN
China
Prior art keywords
glp
buffer
formulation
concentration
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980063594.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN112771073A (zh
Inventor
利塞·吉姆
克拉斯·梅兰德
埃娃·霍恩·默勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zealand Pharma AS
Original Assignee
Zealand Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma AS filed Critical Zealand Pharma AS
Priority to CN202410277209.6A priority Critical patent/CN118267455A/zh
Priority to CN202510255078.6A priority patent/CN120204366A/zh
Publication of CN112771073A publication Critical patent/CN112771073A/zh
Application granted granted Critical
Publication of CN112771073B publication Critical patent/CN112771073B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201980063594.1A 2018-09-28 2019-09-27 胰高血糖素样肽2(glp-2)类似物的制剂 Active CN112771073B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202410277209.6A CN118267455A (zh) 2018-09-28 2019-09-27 胰高血糖素样肽2（glp-2）类似物的制剂
CN202510255078.6A CN120204366A (zh) 2018-09-28 2019-09-27 胰高血糖素样肽2（glp-2）类似物的制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18197755.4 2018-09-28
EP18197755.4A EP3628683A1 (en) 2018-09-28 2018-09-28 Formulations of glucagon-like-peptide-2 (glp-2) analogues
PCT/EP2019/076305 WO2020065064A1 (en) 2018-09-28 2019-09-27 Formulations of glucagon-like-peptide-2 (glp-2) analogues

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202510255078.6A Division CN120204366A (zh) 2018-09-28 2019-09-27 胰高血糖素样肽2（glp-2）类似物的制剂
CN202410277209.6A Division CN118267455A (zh) 2018-09-28 2019-09-27 胰高血糖素样肽2（glp-2）类似物的制剂

Publications (2)

Publication Number Publication Date
CN112771073A CN112771073A (zh) 2021-05-07
CN112771073B true CN112771073B (zh) 2025-07-01

Family

ID=63794308

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201980063594.1A Active CN112771073B (zh) 2018-09-28 2019-09-27 胰高血糖素样肽2(glp-2)类似物的制剂
CN202510255078.6A Pending CN120204366A (zh) 2018-09-28 2019-09-27 胰高血糖素样肽2（glp-2）类似物的制剂
CN202410277209.6A Pending CN118267455A (zh) 2018-09-28 2019-09-27 胰高血糖素样肽2（glp-2）类似物的制剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202510255078.6A Pending CN120204366A (zh) 2018-09-28 2019-09-27 胰高血糖素样肽2（glp-2）类似物的制剂
CN202410277209.6A Pending CN118267455A (zh) 2018-09-28 2019-09-27 胰高血糖素样肽2（glp-2）类似物的制剂

Country Status (14)

Country Link
US (2) US20220265551A1 (https=)
EP (2) EP3628683A1 (https=)
JP (2) JP7566730B2 (https=)
KR (2) KR20260008798A (https=)
CN (3) CN112771073B (https=)
AU (1) AU2019348538B2 (https=)
BR (1) BR112021005858A2 (https=)
CA (1) CA3114330A1 (https=)
CL (1) CL2021000678A1 (https=)
IL (1) IL281362B1 (https=)
MX (2) MX2021003271A (https=)
NZ (1) NZ775113A (https=)
SG (1) SG11202102383VA (https=)
WO (1) WO2020065064A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019026711A2 (pt) 2017-06-16 2020-06-30 Zealand Pharma A/S regimes de dosagem para a administração de análogos de peptídeo semelhante a glucagon- 2 (glp-2)
EP4154869A4 (en) * 2020-05-22 2025-01-22 Hanmi Pharm. Co., Ltd. Liquid formulation of long-acting conjugate of glp-2
MX2023006901A (es) * 2020-12-16 2023-06-26 Zealand Pharma As Uso de analogos de glp-2 en pacientes con insuficiencia renal.
AU2022341538A1 (en) * 2021-09-10 2024-04-11 Zealand Pharma A/S Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues
WO2023118416A1 (en) 2021-12-23 2023-06-29 Zealand Pharma A/S Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues
EP4572783A1 (en) 2022-09-30 2025-06-25 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs)
WO2024075135A1 (en) * 2022-10-03 2024-04-11 Orbicular Pharmaceutical Technologies Private Limited "stable injectable compositions of glp-2 peptide"
IL322328A (en) 2023-01-27 2025-09-01 Zealand Pharma As Glucagon-like peptide-2 (GLP-2) analogs and their medical uses for the treatment of short bowel syndrome (SBS)
WO2025141129A1 (en) 2023-12-28 2025-07-03 Zealand Pharma A/S Formulations of glucagon-like-peptide 2 (glp-2) analogues and their uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101171262A (zh) * 2005-05-04 2008-04-30 西兰制药公司 胰高血糖素样肽-2(glp-2)类似物
CN101573376A (zh) * 2006-11-08 2009-11-04 西兰制药公司 选择性胰高血糖素样肽-2（glp-2）类似物
CN101668535A (zh) * 2006-12-29 2010-03-10 益普生制药股份有限公司 Glp-1药物组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
DE60142885D1 (de) 1996-04-12 2010-10-07 Ontario Inc 1149336 Dem Glukagon ähnliches Peptid-2
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
WO2001041779A2 (en) 1999-12-08 2001-06-14 1149336 Ontario Inc. Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
ATE396202T1 (de) 2001-02-16 2008-06-15 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
EP2119724A1 (en) * 2005-05-03 2009-11-18 Novetide Ltd. Solid-phase process foor the preparation of goserelin
CN101341254A (zh) * 2005-12-24 2009-01-07 蒂加斯克乳制品研究中心 反-10，顺-12十八碳二烯酸的生产方法
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
CA2798518A1 (en) * 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide
FR2994390B1 (fr) * 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
PT2922530T (pt) * 2012-11-20 2016-12-22 Fresenius Kabi Usa Llc Formulações de acetato de caspofungina
AU2015335743B2 (en) * 2014-10-23 2020-12-24 Amgen Inc. Reducing viscosity of pharmaceutical formulations
EP4591853A1 (en) * 2016-11-21 2025-07-30 Amylyx Pharmaceuticals, Inc. Buffered formulations of exendin (9-39)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101171262A (zh) * 2005-05-04 2008-04-30 西兰制药公司 胰高血糖素样肽-2(glp-2)类似物
CN101573376A (zh) * 2006-11-08 2009-11-04 西兰制药公司 选择性胰高血糖素样肽-2（glp-2）类似物
CN101668535A (zh) * 2006-12-29 2010-03-10 益普生制药股份有限公司 Glp-1药物组合物

Also Published As

Publication number Publication date
US20220265551A1 (en) 2022-08-25
CN118267455A (zh) 2024-07-02
EP3856766A1 (en) 2021-08-04
IL281362B1 (en) 2026-03-01
MX2026000859A (es) 2026-03-02
NZ775113A (en) 2026-01-30
MX2021003271A (es) 2021-05-12
JP2022502432A (ja) 2022-01-11
CA3114330A1 (en) 2020-04-02
EP3628683A1 (en) 2020-04-01
KR20260008798A (ko) 2026-01-16
JP7738136B2 (ja) 2025-09-11
AU2019348538B2 (en) 2025-04-03
JP2024156754A (ja) 2024-11-06
US20240065978A1 (en) 2024-02-29
BR112021005858A2 (pt) 2021-07-27
IL281362A (en) 2021-04-29
CL2021000678A1 (es) 2021-08-06
SG11202102383VA (en) 2021-04-29
CN120204366A (zh) 2025-06-27
WO2020065064A1 (en) 2020-04-02
KR20210069056A (ko) 2021-06-10
AU2019348538A1 (en) 2021-05-20
JP7566730B2 (ja) 2024-10-15
CN112771073A (zh) 2021-05-07

Similar Documents

Publication Publication Date Title
CN112771073B (zh) 胰高血糖素样肽2(glp-2)类似物的制剂
JP7580404B2 (ja) Ｇｌｐ１／２二重アゴニストの非経口医薬組成物
EP4096702A1 (en) Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
EP3856767B1 (en) Formulations of glucagon-like-peptide-2 (glp-2) analogues
US20240299552A1 (en) Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists
US20230405088A1 (en) Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists
AU2021404497A1 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
RU2833459C2 (ru) Составы аналогов глюкагоноподобного пептида-2 (glp-2)
KR20230121853A (ko) 신부전증 환자에서 glp-2 유사체의 용도
TW202535919A (zh) 類升糖素肽2(glp-2)類似物之調配物及其用途
RU2815643C2 (ru) Фармацевтическая парентеральная композиция двойного агониста glp1/2
HK40104625B (en) Liquid formulations of amylin analogues
HK40104625A (en) Liquid formulations of amylin analogues

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant